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Abstract 
Interstitial lung disease (ILD) induced by epidermal growth factor receptor tyrosine 
kinase inhibitors (EGFR-TKIs), such as gefitinib and erlotinib, is a rare but fatal 
complication of TKI treatment. Transfer to chemotherapy or continuation with TKI of 
reduced dose are alternative treatment strategies. We report a case of severe ILD in a 
non-small cell lung cancer patient treated with gefitinib. She experienced partial 
response with restarted low-dose EGFR-TKI erlotinib and corticosteroid treatment. 
 
Introduction 
The epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as 
gefitinib and erlotinib, have been shown to have significant antitumor activity in non-
small cell lung cancer (NSCLC) patients with EGFR mutations. Although the common 
side effects of EGFR-TKIs (including skin rash, diarrhea, asthenia and anorexia) are mild 
and controllable, interstitial lung disease (ILD) remains a rare but always fatal 
complication. The disease will relapse after EGFR-TKI suspension which is mandatory to 
rescue the patients who contracted the ILD. We report a case of severe ILD in a NSCLC 
patient treated with gefitinib. She experienced partial response with restarted low-dose 
EGFR-TKI erlotinib and corticosteroid treatment. Case Rep Oncol 2011;4:464–466 
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Case Report 
A 41-year-old woman who complained of non-productive cough and breathlessness was diagnosed 
with lung adenocarcinoma stage IV (T2aN3M1a) in November 2009. Chest computed tomography (CT) 
revealed a 3.0 × 2.6-cm mass in the left lower lobe and left pleural effusion (fig. 1a). EGFR mutation 
status was not evaluated. Because first-line chemotherapy with paclitaxel plus cisplatin cannot be 
tolerated for grade 3 gastrointestinal side effects, she received gefitinib 250 mg/day as second-line 
treatment. Only 7 days after the start of gefitinib, the symptoms disappeared. However after 20 days’ 
treatment of gefitinib, the patient reported high fever and severe respiratory distress on effort. Despite 
high-flow supplemental oxygen delivered via nasal cannula, hypoxemia developed with a PaO2 of less 
than 45 mm Hg. A chest CT revealed bilateral pulmonary infiltrates, patchy airspace consolidation, and 
air bronchograms despite decreased size of the primary tumor (fig. 1b). The diagnosis of EGFR-TKI-
induced interstitial lung disease was made, and gefitinib therapy was stopped. Mechanical ventilation 
and corticosteroid treatment (120 mg/day of intravenous methylpredonisolone) were started 
immediately. The patient experienced improvement and weaned from the ventilator after 8 days of 
treatment. Repeated CT scan showed complete resolution of infiltrates. The corticosteroid was tapered 
over 1 month. 
In June 2010, the patient developed progressive disease after 4 cycles of docetaxel-cisplatin 
chemotherapy (fig. 1c). From July 2010, erlotinib (75 mg/day) was prescribed with oral prednisolone (20 
mg/day). She achieved a partial response after 1 month’s treatment of erlotinib (fig. 1d). The 
prednisolone was withdrawn after 3 months without recurrence of EGFR-TKI-induced ILD. She is still 
alive 1 year after the restart of EGFR-TKI therapy. 
Discussion 
The worldwide incidence of ILD is about 1% in both gefitinib- or erlotinib-treated 
patients; ILD was reported to have a prevalence of 3.5% and mortality of 1.6% in gefitinib-
treated patients in Japan [1]. For the patients who had partial or complete response to 
gefitinib and experienced gefitinib-induced ILD, obligatory suspension of EGFR-TKI 
treatment will cause progression of disease. After recovery from ILD, most of the patients 
received chemotherapy, which is not as effective as EGFR-TKI. Although a case with 
recurrent gefitinib-induced ILD was reported [2], a reduced dose of gefitinib might 
induce a response without recurrent gefitinib-induced ILD [3]. Several cases of NSCLC 
successfully rechallenged with erlotinib after developing gefitinib-induced ILD were also 
described [4, 5]. We add another case report which shows that a reduced dose of erlotinib 
in combination with steroid therapy achieved partial response in a patient recovered from 
gefitinib-induced ILD. So a reduced dose of erlotinib seems to be a potential therapeutic 
option for the treatment of NSCLC patients who develop gefitinib-induced ILD, although 
it is required to pay attention to the possibility of the development of recurrent ILD. The 
underlying mechanisms of ILD and strategies to overcome TKI resistance are warranted 
further investigation. 
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Fig. 1. a CT scan shows a mass in the left lower lobe at the diagnosis of lung adenocarcinoma. b Chest 
CT after gefitinib treatment revealed patchy airspace consolidation and air bronchograms despite 
decreased size of the primary tumor. c Chest CT revealed progress of disease after 4 cycles of 
chemotherapy. d After one month of treatment of erlotinib, a partial response was seen. 
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